Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors

BACKGROUND: Monoamine oxidase inhibitors (MAOIs) are being developed for major depressive disorder, Alzheimer’s, and Parkinson’s Disease. Newer MAOIs have minimal sensitivity to tyramine, but a key limitation for optimizing their development is that standards for in vivo monoamine oxidase-A (MAO-A)...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiuccariello, Lina, Cooke, Robert G, Miler, Laura, Levitan, Robert D, Baker, Glen B, Kish, Stephen J, Kolla, Nathan J, Rusjan, Pablo M, Houle, Sylvain, Wilson, Alan A, Meyer, Jeffrey H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772270/
https://www.ncbi.nlm.nih.gov/pubmed/26316187
http://dx.doi.org/10.1093/ijnp/pyv078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772270/
https://www.ncbi.nlm.nih.gov/pubmed/26316187
http://dx.doi.org/10.1093/ijnp/pyv078

Ejemplares similares